Evidence map›Paper›PMID 29731983›Full record

ArticleOncotarget2018

Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients.

Valeriy Poroyko, Tamara Mirzapoiazova, Arin Nam, Isa Mambetsariev, Bolot Mambetsariev, Xiwei Wu, Aliya Husain, Everett E Vokes, Deric L Wheeler, Ravi Salgia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Exosomal microRNAs in non-small cell lung cancer.Translational cancer research · 2021
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Valeriy PoroykoDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.
Tamara MirzapoiazovaDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.
Arin NamDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.
Isa MambetsarievDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.
Bolot MambetsarievDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.
Xiwei WuDepartment of Molecular and Cellular Biology, City of Hope National Medical Center, Duarte, CA, USA.
Aliya HusainDepartment of Medicine, University of Chicago, Chicago, IL, USA.
Everett E VokesDepartment of Medicine, University of Chicago, Chicago, IL, USA.
Deric L WheelerDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Ravi SalgiaDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA.

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3M
Project 2: Targeting Cooperative Phenotypes Common in Spatial HeterogeneityU54CA209978 · NCI · UNIVERSITY OF UTAH · PI BILD, ANDREA HOPE · 2017 to 2021
$10.5M
NCI NIH HHS P30 CA033572NCI NIH HHS U54 CA209978
6 · The paper itself

Abstract

Lung cancer is a devastating disease with overall bleak prognosis. Current methods to diagnose lung cancer are rather invasive and are inadequate to detect the disease at an early stage when treatment is likely to be most effective. In this study, a shotgun sequencing approach was used to study the microRNA (miRNA) cargo of serum-derived exosomes of small cell lung cancer (SCLC) (n=9) and non-small cell lung cancer (NSCLC) (n=11) patients, and healthy controls (n=10). The study has identified 17 miRNA species that are differentially expressed in cancer patients and control subjects. Furthermore, within the patient groups, a set of miRNAs were differentially expressed in exosomal samples obtained before and after chemotherapy treatment. This manuscript demonstrates the potential of exosomal miRNAs for developing noninvasive tests for disease differentiation and treatment monitoring in lung cancer patients.

Indexed as

exosomeliquid biopsymiRNANSCLCSCLC

Identifiers

PMID29731983
PMCPMC5929426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.